Drugs / Ketanserin

Trials 8 · a red edge is where a trial was stopped

PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 01 trial
Phase 0 NCT03321136 Nov 2017 → Jul 2019 University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 13 trials
Phase 1 NCT06796361 Apr 2025 → Aug 2026 overdue University Hospital, Basel, Switzerland Recruiting No outcome recorded
Phase 1 NCT04558294 Oct 2020 → Aug 2021 University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 1 NCT03289949 Mar 2017 → Jun 2030 expected Gitte Moos Knudsen Recruiting No outcome recorded
Phase 32 trials
Phase 3 NCT01329887 Mar 2011 → May 2014 infectious disease with sepsis Frisius Medisch Centrum Completed No outcome recorded
Phase 3 NCT00557219 Apr 2008 → Apr 2015 acute kidney injury Medical University of Gdansk Terminated No outcome recorded
Phase 41 trial
Phase 4 NCT03646318 Sep 2018 → Apr 2019 Onze Lieve Vrouwe Gasthuis Unknown No outcome recorded
Phase not applicable1 trial
NCT02451072 Mar 2015 → Jan 2016 Psychiatric University Hospital, Zurich Completed No outcome recorded
Also used as a comparator or background therapy in 4 trials
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 13 trials
Phase 1 NCT06899334 Background Apr 2025 → Aug 2026 overdue University Hospital, Basel, Switzerland Recruiting No outcome recorded
Phase 1 NCT05964647 Comparator Feb 2024 → Jun 2025 University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 1 NCT04849013 Comparator Aug 2021 → Mar 2023 University Hospital, Basel, Switzerland Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT02632877 Comparator Jan 2014 → Nov 2015 ulcer of lower limbs University of Guadalajara Completed No outcome recorded

Evidence & citations 14 cited values

Every value below carries the sentence it was read from. 14 sources stand behind the page.

FieldValueCited text
Known as ketanserin “A moderate to high oral dose of 150 µg LSD will be administered followed by 20 mg intravenous ketanserin after 3 h” NCT06899334
11

“0.2 mg LSD plus 40 mg ketanserin per os, single doses each” NCT03321136

NCT05964647

NCT03646318

NCT03289949

NCT04849013

NCT06796361

NCT02632877

NCT00557219

NCT02451072

NCT04558294

NCT01329887

Known as KETANSERIN TARTRATE ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as Ketanserina ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as Ketanserine ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as KJK 945 ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as NSC-758959 ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as Perketan ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as R 49945 ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as R-41,468 ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as Serepress ChEMBL registry synonym — accepted as the source's own label CHEMBL51
Known as Sufrexal “ketanserin (Sufrexal)” NCT00557219
Action Inhibit “Ketanserin blocks a protein called the serotonin 2A receptor” PMID 30355445 Oct 2018
Modality Small molecule CHEMBL51
Route Intravenous “continuous intravenous infusion 0.1 mg/kg/hour ketanserin for 24 hours” NCT00557219